Compare CELZ & NXGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELZ | NXGL |
|---|---|---|
| Founded | 1998 | 1997 |
| Country | United States | United States |
| Employees | 4 | 19 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.9M |
| IPO Year | 2008 | N/A |
| Metric | CELZ | NXGL |
|---|---|---|
| Price | $0.74 | $0.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 7.8M | 116.6K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,000.00 | N/A |
| Revenue This Year | N/A | $50.77 |
| Revenue Next Year | N/A | $46.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $0.41 |
| 52 Week High | $6.25 | $2.89 |
| Indicator | CELZ | NXGL |
|---|---|---|
| Relative Strength Index (RSI) | 27.03 | 41.87 |
| Support Level | N/A | N/A |
| Resistance Level | $0.93 | $0.64 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 8.08 | 28.75 |
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.